3D In Vitro Human Organ Mimicry Devices for Drug Discovery, Development, and Assessment

Table 7

Summary of recent advancements in in vitro models in brain toxicity testing including the type of drug, the application, the applied cell lines, and the kinetics.

Drug type	Application	Applied cell lines	Kinetics	Ref(s)
Amyloid-β	Toxicity (disease mimic)	Neural progenitor suspension (cortical rat cells)	Over 10 days	[125]
CXCL12, SLIT2-N	Chemotactic effect	Progenitor hNT2, primary hNPC, hBMECs	8 weeks	[143]
Antihuman transferrin receptor (MEM-189), MoAb	Transcytosis	TY10, hBPCT, hAst		[131]
Dextran	Permeability	Astrocytes (pup), primary cortical cells (rat), HUVEC	Over 7 days	[130]
		hCMEC/D3	Over 4 days	[144]

CXCL12, SLIT2-N: chemokines; hNT2: human teratocarcinoma cells; hNPC: human fetal neural progenitor cells; hBMECs, TY10: human brain microvascular endothelial cells; MoAb: monoclonal antibody; hBPCT: human brain pericyte; hAst: human astrocytes; HUVECs: human umbilical vein endothelial cells; hCMEC/D3: human cerebral microvascular endothelial cell line; TEER: transendothelial electrical resistance.